Research Topics
| Catherine PatteSummaryAffiliation: Institut Gustave Roussy Country: France Publications
| Collaborators
|
Detail Information
Publications
Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric OncologyC Patte
Department of Pediatrics, Institut Gustave Roussy, Villejuif, France
J Clin Oncol 20:441-8. 2002..To determine whether granulocyte colony-stimulating factor (G-CSF; lenograstim) decreases the incidence of febrile neutropenia after induction courses in treatment of childhood non-Hodgkin's lymphoma (NHL)...- Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patientsCatherine Patte
Institut Gustave Roussy, Pediatric Department, Villejuif, France
Blood 109:2773-80. 2007..3 g/m2 cyclophosphamide and 120 mg/m2 doxorubicin... - [Non Hodgkin's lymphoma in adolescents]Catherine Patte
Departement de Pediatrie, Institut Gustave Roussy, rue Camille Desmoulins, 94800 Villejuif
Bull Cancer 94:339-48. 2007.... - [Good prognosis childhood cancers]Catherine Patte
Département de p ediatrie, Institut Gustave Roussy, 94805 Villejuif Cedex
Rev Prat 57:1070-6. 2007..The knowledge of low risk groups of patients allows the decrease of cumulative doses of alkylating agents and anthracyclines and limits the use of irradiation in order to reduce long term sequelae... - Treatment of mature B-ALL and high grade B-NHL in childrenCatherine Patte
Paediatric Department, Institut Gustave Roussy, rue Camille Desmoulins, Villejuif, Cedex, 94800, France
Best Pract Res Clin Haematol 15:695-711. 2002..A patient who remains for 1 year in complete remission can be considered as cured, because all relapses occur early within the first year after diagnosis... - Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocolC Patte
Institut Gustave Roussy, Villejuif, France
Ann Oncol 13:789-95. 2002.... - The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemiaC Patte
Pediatrics Department, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
Blood 97:3370-9. 2001..CNS involvement was the only prognostic factor in group C. (Blood. 2001;97:3370-3379).. - [Malignant ovarian tumors in childhood]D Valteau-Couanet
, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif
Arch Pediatr 15:781-2. 2008 - Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric OncologyL Brugieres
Department of Pediatric Oncology, Institut Gustave Roussy, Villejuif, France
Ann Oncol 11:53-8. 2000..To study response to chemotherapy and the outcome of children treated for a relapsed anaplastic large-cell lymphoma (ALCL) and to evaluate the role of bone marrow transplantation (BMT) in these patients... - [Treatment of childhood cancer in Africa. Action of the Franco-African childhood cancer group]J Lemerle
GFAOP, Institut Gustave Roussy, Villejuif, France
Med Trop (Mars) 67:497-504. 2007..e., one for acute lymphoblastic leukemia and the other for Hodgkin's disease. Two other projects are being planned, i.e., one for treatment of retinoblastoma and the other for treatment of some types of brain tumors... - High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)E Jabbour
, Institut Gustave Roussy, Villejuif, France
Leukemia 20:814-9. 2006..The Ann Arbor stage, age and serum lactate dehydrogenase level did not influence outcomes. This LMT-89 protocol is a safe regimen and is highly effective in advanced LL without bone marrow involvement... - Alagille syndrome and nephroblastoma: Unusual coincidence of two rare disordersFranck Bourdeaut
Institut Curie, Departement de Pediatrie, Paris F 75246, France
Pediatr Blood Cancer 50:908-11. 2008..In one nephroblastoma an additional somatic 1p36 deletion was present. The link between Alagille syndrome, JAG1 alterations and nephroblastoma is discussed... - Survival in France after childhood acute leukaemia and non-Hodgkin's lymphoma (1990-2000)A Goubin
INSERM, U754, Villejuif, France
Eur J Cancer 42:534-41. 2006..Down's syndrome was associated with poor survival after ALL. No gender-related variations in survival were in evidence. The results reported herein are similar to those reported by other European registries and clinical trials... - [The French-African paediatric oncology group: a first stage report]J Lemerle
Institut Gustave-Roussy, 94, Villejuif, France
Arch Pediatr 12:848-50. 2005 - European experience in the treatment of hyperuricemiaC Patte
Pediatric Oncology Department, Institut Gustave-Roussy, Villejuif, France
Semin Hematol 38:9-12. 2001.... - High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphomaSaloua Toujani
CNRS, FRE2939, Génomique Cellulaire des Cancers, Institut Gustave Roussy IGR, Villejuif, France
PLoS ONE 4:e7089. 2009..Further investigations which combined gene expression and functional studies are essential to understand the lymphomagenesis mechanism and for the development of more effective, targeted therapeutic strategies... - Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric OncologyLaurence Brugieres
Department of Pediatric Oncology, Institut Gustave Roussy, Villejuif, France
J Clin Oncol 27:5056-61. 2009..To evaluate the efficacy of vinblastine for relapsed/refractory anaplastic large-cell lymphoma (ALCL)... - Role of parenteral antibiotherapy in gastrointestinal tract flora suppression. A study in children treated with high-dose chemotherapy and autologous bone marrow transplantationP Chastagner
Department of Pediatrics, Institut Gustave Roussy, Villejuif, France
Bone Marrow Transplant 4:393-8. 1989..Since parenteral antibiotherapy alone was able to suppress the gastrointestinal tract flora, the effects of this treatment should be considered in all trials of digestive tract decontamination... - Testicular disease in childhood B-cell non-Hodgkin's lymphoma: the French Society of Pediatric Oncology experienceJ H Dalle
Service d Oncologie Pédiatrique and Département d Oncologie Pédiatrique, Institut Gustave Roussy, Villejuif, France
J Clin Oncol 19:2397-403. 2001..To investigate whether testicular disease in childhood B-cell lymphoma should continue to be considered a sanctuary site, as it is with other lymphoid malignancies such as acute lymphoblastic leukemia... - [Malignant primary cardiac tumors in childhood and adolescence]B Fresneau
Service d Oncologie Pediatrique, Institut Gustave Roussy, rue Camille Desmoulins, 94800 Villejuif, France
Arch Pediatr 17:495-501. 2010..Chemotherapy is the main treatment, and surgery has to be used only when complications occur. Prognosis depends on histology and not lymphoma location, and so is better than the prognosis for sarcoma... - Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international studyMary Gerrard
Sheffield Children s Hospital, Sheffield, UK
Br J Haematol 141:840-7. 2008..5 months, the 4 year event-free survival is 98.3% and overall survival is 99.2%. Children with resected localized B-NHL can be cured with minimal toxicity following two courses of low intensity treatment without IT chemotherapy... - [Therapeutic progress in acute lymphoblastic leukemias and stage IV Burkitt-type lymphomas in children]Guy Leverger
Bull Acad Natl Med 187:743-55; discussion 755-7. 2003..Relapse cases, occurring always early, still have a very bad prognosis and remain a challenge for the future... - Treatment of B-cell lymphoma with LMB modified protocols in Africa--report of the French-African Pediatric Oncology Group (GFAOP)Mhamed Harif
Service d hématologie et oncologie pédiatrique, hôpital 20 Août 1953, Casablanca, Morocco
Pediatr Blood Cancer 50:1138-42. 2008..Eight pediatric oncology units from Algeria, Cameroon, Madagascar, Morocco, Tunisia, and Senegal have been involved... - Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groupsMarry M van den Heuvel-Eibrink
Department of Pediatric Oncology Hematology Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
Pediatr Blood Cancer 50:1130-4. 2008..To review the clinical characteristics and survival of infants diagnosed with a primary renal tumor in the first 7 months of life... - Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescentsMitchell S Cairo
Morgan Stanley Children s Hospital of New York Presbyterian, Columbia University, New York, NY 10032, USA
Blood 109:2736-43. 2007..001). Standard-intensity FAB/LMB therapy is recommended for children with high-risk B-NHL (B-ALL with or without CNS involvement)... - SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational surveyYves Bertrand
Service d Hématologie Pédiatrie, Hopital Debrousse, Lyon, France
J Pediatr Hematol Oncol 30:267-71. 2008..One patient required hemodialysis. Only minor adjustments to the SFCE recommendations were required to ensure the optimal use of rasburicase in pediatric patients at risk of TLS... - Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumourDominique Baudry
INSERM U383, Hopital Necker Enfants Malades, Universite Rene Descartes, 75743 Paris Cedex 15, France
Oncogene 21:5566-73. 2002..Moreover, our results suggest that the VEGF expression level may be of prognosis relevance for relapsed patients... - Cadherins in Wilms' tumor: E-cadherin expression despite absence of WT1Dominique Baudry
INSERM U383, , , Paris, France
Anticancer Res 23:475-8. 2003..Our data suggest (i) the existence of alternative mechanisms for regulating E-CAD expression, and (ii) that E-CAD does not belong to the WT1 pathway that is altered in Wilms' tumorigenesis... - Education and health promotion in adolescent and young adult cancer survivorsMelissa M Hudson
Department of Clinical Oncology and Division of Cancer Survivorship, St Jude Children s Research Hospital, The University of Tennessee, College of Medicine, Memphis, Tennessee 38105, USA
Pediatr Blood Cancer 50:1105-8. 2008..To effectively integrate lifestyle interventions into pediatric oncology care, prioritization and funding of health promotion research efforts must be comparable to that of disease control in frontline cancer trials... - Mature B-cell lymphoma in children and adolescents: International group pathologist consensus correlates with histology technical qualityMark A Lones
Children s Cancer Group CCG now part of Children s Oncology Group, Operations Center, 440 E Huntington Drive, PO Box 60012, Arcadia, CA 91066 6012, USA
J Pediatr Hematol Oncol 28:568-74. 2006..Poor HTQ may adversely impact diagnostic ability and affect prognosis and therapeutic management when different treatment regimens are employed for DLBCL versus BL/BLL... - Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in childrenNicolas Kalfa
Unité d Endocrinologie Gynécologie Pédiatrique, Service de pédiatrie 1, Hopital Arnaud de Villeneuve, Montpellier, France
Fertil Steril 87:896-901. 2007..The aim of this multicentric nationwide study was to determine whether FOXL2 expression varies during tumoral proliferation of GC cells in juvenile ovarian GC tumors (OGCT)...